Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
about
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesProstate cancer relevant antigens and enzymes for targeted drug deliveryCritical Roles of Hydrophobicity and Orientation of Side Chains for Inactivation of Sarcoplasmic Reticulum Ca2+-ATPase with Thapsigargin and Thapsigargin AnalogsOptimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancerSelf-assembled gold nanoparticle molecular probes for detecting proteolytic activity in vivo.Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors.A strategy for the selective imaging of glycans using caged metabolic precursors.A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic diseaseProteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activityStructural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitorsProstate-specific antigen modulates the expression of genes involved in prostate tumor growthEnzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles.Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.Characterization of the prostate-specific antigen (PSA) catalytic mechanism: a pre-steady-state and steady-state study.Protease-activated drug development.Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.Molecular insights into substrate specificity of prostate specific antigen through structural modelingProstate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.Kallikreins - The melting pot of activity and functionA prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.Protease activation of split green fluorescent proteinA biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice.Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.Protease-activated pore-forming peptides for the treatment and imaging of prostate cancerProstate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancerPotent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ionsAnticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.Inhibition of the sarco/endoplasmic reticulum (ER) Ca2+-ATPase by thapsigargin analogs induces cell death via ER Ca2+ depletion and the unfolded protein response.Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer.Gold nanoparticle-based colorimetric method for the detection of prostate-specific antigen.
P2860
Q24594742-4BE55C97-575E-4E5A-B41F-7D2B4051804FQ26865810-8EC62DEF-5BFF-4EB0-BFD4-B6A1018D9B40Q27013843-358A6959-50B5-4A84-8C14-558C91DB65F3Q27662332-FD4E5738-DFD7-403B-A5FE-661F0D750481Q33471057-6A27F85A-33F5-49B1-94F4-8A113D0A6431Q33530511-CB9E49FA-30B6-4798-B921-5E76CB192515Q33908164-09FF4253-89D3-4B59-A48A-3BC3CB1F37C1Q34010347-DA61E420-C288-4EBE-9244-A3047B51E692Q34049107-57B0BD2D-20E2-49D0-A4F2-BFCD1E77298DQ34215885-E273692E-4DC4-43D8-A619-9E1A86B548EAQ34732727-49ADD580-01E3-4FC9-88DD-8161E953C49DQ34768349-EF59D416-A35B-499E-94F0-CF54CF76DBF8Q35027986-D81ACD04-EC95-4672-B326-122AB3FB7F41Q35048230-4D8DABC3-85DE-4BE6-B116-785AF50FE5D3Q35214106-98FBADB5-5ABE-4B4F-8A23-592DEC7BE87AQ35811508-DB901981-8AAF-4CB0-8A5A-C424677FA7C4Q35838103-09997CC4-4C53-411E-8F66-CF20FBF1DA92Q36027178-078C11CA-B82C-43C9-85E5-C529FF926160Q36266738-CC8AC204-3921-4D0E-984D-8FB11632CAA6Q36563056-57B7A193-C0A5-439D-8AF4-2299C6F6E572Q36776738-DF69C991-532D-460D-877B-039F73CD3511Q37013419-D4D55A6D-FAA1-4C98-81DC-BA56A5D16100Q37331739-2A3272E0-8C1C-4854-B317-D9B3AED0E487Q37697815-6CD7968E-E8D6-4F99-871C-EBD5DC434811Q38925667-EA21169F-D342-4E42-AF06-57BA68638815Q39789912-49D32A21-FC39-4BD6-A9B0-31228DCDB389Q41860731-1683F731-94AD-44EF-8973-B87AB5F40825Q41893698-E280BCA4-E87B-44A4-AF56-BB10FCD78D9FQ41983632-1C44FD73-A0A9-4947-A690-B5FC22071A01Q42177972-9362625A-BEE5-47ED-9B3D-0BFA998998FCQ42589831-D877063A-17D8-484E-9AD4-8E877D1899F4Q47387421-EA31E397-2071-4821-A9DD-CC4D01054171Q47709017-91F83EF0-25FF-46D8-B598-1FB11E66B2CFQ53259763-25A5089C-3836-49FA-B026-F86BAEA4D361Q55018508-E952AD13-305D-4F73-AA3B-B27DF2C0AF7DQ55024934-EAAF263C-6ACA-425B-9351-1666FA698917
P2860
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Specific and efficient peptide ...... of prostate-specific antigen.
@ast
Specific and efficient peptide ...... of prostate-specific antigen.
@en
Specific and efficient peptide ...... of prostate-specific antigen.
@nl
type
label
Specific and efficient peptide ...... of prostate-specific antigen.
@ast
Specific and efficient peptide ...... of prostate-specific antigen.
@en
Specific and efficient peptide ...... of prostate-specific antigen.
@nl
prefLabel
Specific and efficient peptide ...... of prostate-specific antigen.
@ast
Specific and efficient peptide ...... of prostate-specific antigen.
@en
Specific and efficient peptide ...... of prostate-specific antigen.
@nl
P2093
P2860
P1433
P1476
Specific and efficient peptide ...... y of prostate-specific antigen
@en
P2093
P2860
P304
P407
P577
1997-11-01T00:00:00Z